title: Peri-operative biology in primary breast cancer: a credible therapeutic target.
abstract: Over the last 25 years, there has been a growing body of basic science, modeling, and clinical data suggesting that the peri-operative period in the treatment of primary breast cancer is dynamic and can be manipulated to improve long-term outcomes. Clinical data have demonstrated early peaks of hazards for recurrence and emphasized the relationship of these to peri-operative events. More recently, clinical trial data with surgical oophorectomy at different times in the menstrual cycle, peri-operative progesterone, and anti-inflammatory drugs suggest that interventional studies are particularly well justified, given the increasing recognition of the costs both financially and clinically of current systemic regimens.
authors.affiliation: The Amader Gram Cancer Care and Research Center, Rampal, Bangladesh. richardibcrf@gmail.com.|, 2708 Columbia Road, Madison, WI, 53705, USA. richardibcrf@gmail.com.
authors.forename: Richard R
authors.initials: RR
authors.lastname: Love
authors.affiliation: The Dr. Susan Love Research Foundation Los Angeles, Encino, CA, USA.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Love
mesh_terms: D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000191:economics / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D019468:Disease Management; D005260:Female; D006801:Humans; D010052:Ovariectomy / Q000191:economics / Q000379:methods; D019990:Perioperative Care / Q000191:economics; D011374:Progesterone / Q000191:economics / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D011374:Progesterone
keywords: Cell-signaling; Peri-operative biology; Surgery